2:51 PM
 | 
Mar 13, 2018
 |  BC Extra  |  Clinical News

MorphoSys planning BLA for DLBCL candidate on Phase II data

MorphoSys AG (Xetra:MOR; Pink:MPSYY) said it discussed with FDA the possibility of expedited regulatory submission and approval for its MOR208 to treat relapsed or refractory diffuse large B cell lymphoma "based primarily" on data from the Phase II L-MIND trial in the indication. The company, which plans to submit a rolling BLA to FDA in 2H19...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >